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Introduction
Gout is a form of inﬂ  ammatory arthritis that is charac-
terized initially by acute attacks of active synovitis related 
to the presence of monosodium urate (MSU) crystals in 
the joints and periarticular soft tissues. Chronic gouty 
arthropathy may supervene after a period of years, 
featuring ongoing synovitis in peripheral and, occasionally, 
axial joints, often associated with the presence of tophi 
and accom  panied by bone erosion. Plain radiography 
(XR) tends to be normal in early gout, but in chronic 
gout, typically after 7 to 10 years, ‘punched out’ 
extramarginal, articular, or para-articular erosions may 
become apparent with typical preservation of the joint 
space and bone density [1]. In advanced tophaceous 
disease, extreme bone destruction can develop with large 
periarticular lytic lesions associated with apparent joint 
space widening (Figure  1) [2], and concomitant osteo-
arthritis frequently accompanies these changes, espe-
cially in the feet.
In recent years, advanced imaging techniques, includ-
ing magnetic resonance imaging (MRI), computed tomo-
graphy (CT) using high-resolution multislice scanners, 
and ultrasonography (US), have led to new insights into 
the pathology of many forms of inﬂ  ammatory arthritis 
[3]. Scoring systems have been developed to quantify 
joint inﬂ  ammation and destruction by using imaging and 
these are now in routine use in clinical trials to provide 
sensitive measures of drug eﬃ   cacy  in  rheumatoid 
arthritis (RA) and psoriatic arthritis (PsA) [4,5]. In gout, 
the applications of advanced imaging are only now 
starting to be explored and are of particular relevance to 
the clinician assessing the impact of urate-lowering 
therapies [6]. Th  ese applications include (a) imaging to 
investigate joint pathology in gout, (b) imaging to assist 
in the diagnosis of gout, and (c) monitoring of joint 
inﬂ   ammation and damage, especially in response to 
therapy. Th  is review presents a critical appraisal of the 
current literature pertaining to advanced imaging in gout 
and provides speciﬁ  c discussion of these areas related to 
each modality.
1. Joint pathology in gout
Before the advent of advanced imaging, an understanding 
of the pathology of gout was based primarily on light 
microscope examination of tophi and periarticular bone, 
supplemented by XR to deﬁ   ne the radiographic mor-
phology and distribution of erosions [7]. Th  is approach 
was biased toward investigating severe erosive gouty 
arthropathy, and specimens obtained for histopathology 
were usually derived from amputated digits or limbs, 
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There are many exciting new applications for advanced 
imaging in gout. These modalities employ multiplanar 
imaging and allow computerized three-dimensional 
rendering of bone and joints (including tophi) and 
have the advantage of electronic data storage for later 
retrieval. High-resolution computed tomography has 
been particularly helpful in exploring the pathology of 
gout by investigating the relationship between bone 
erosions and tophi. Magnetic resonance imaging and 
ultrasonography can image the infl  ammatory nature 
of gouty arthropathy, revealing synovial and soft tissue 
infl  ammation, and can provide information about the 
composition and vascularity of tophi. Dual-energy 
computerized tomography is a new modality that is 
able to identify tophi by their chemical composition 
and reveal even small occult tophaceous deposits. All 
modalities are being investigated for their potential 
roles in diagnosis and could have important clinical 
applications in the patient for whom aspiration of 
monosodium urate crystals from the joint is not 
possible. Imaging can also provide outcome measures, 
such as change in tophus volume, for monitoring 
the response to urate-lowering therapy and this is an 
important application in the clinical trial setting.
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© 2011 BioMed Central Ltdwhere chronically discharging tophi were often secon-
darily infected [8]. By contrast, advanced imaging tech-
niques open a window into the pathology of gout at any 
stage of the disease process, including at presentation 
and in early disease, when XRs are characteristically 
normal and histopathological specimens are unavailable.
Computed tomography reveals tophi adjacent to erosions
Using advanced multislice CT scanning, our own group 
investigated the question of whether tophi were likely to 
be responsible for bone erosion in gout – an impression 
gained from XR review but not previously conﬁ  rmed by 
using a multiplanar high-deﬁ   nition modality. Paired 
radio  graphs and CT scans were available for investigation 
in a total of 798 individual hand and wrist joints. For 
those bones with large radiographic erosions, 96 out of 
98 (98%) had CT evidence of associated tophus. For CT 
erosions, 82% had visible intraosseous tophi; of the larger 
erosions (measuring greater than 7.5 mm in diameter), 
100% (56 out of 56) contained tophi. Th  ere was also a 
very strong correlation between the diameters of CT 
erosions and intraosseous tophi (r = 0.93), indicating that 
the gouty tophus sits snugly in its pocket of bone, which 
may be entirely intraosseous or have a cortical breach, 
which, if proﬁ  led on XR, will appear as a typical gouty 
erosion. Figure  2 shows a three-dimensional (3D) 
reconstruction of a CT scan revealing discrete tophi at 
multiple sites adjacent to bone and within soft tissues.
The magnetic resonance imaging view of tophi
MRI scanning can also be used to image tophi, and the 
information this modality reveals about the inﬂ  ammatory 
nature of these lesions cannot be appreciated from XR or 
CT scanning. On MRI, tophi typically exhibit low signal 
on T1-weighted images and medium to high signal on 
T2-weighted (T2w) images, indicating the presence of 
cellular tissue surrounding or inﬁ  ltrating the crystalline 
mass [9,10]. Th  e vascularity of this tissue will inﬂ  uence 
the degree of MRI post-contrast enhancement (Figure 3), 
and calciﬁ  cation within the tophus can lead to regions of 
low signal on T2w images [9]. Th   ese features are consis-
tent with the characteristics of tophi that have been 
excised and examined using the tools of immuno-
histochemistry. Palmer and colleagues [11] described the 
structure of a typical tophus as consisting of a mostly 
acellular crystalline core surrounded by a ‘corona zone’ 
and an outer, loose ‘ﬁ   brovascular zone’. Dalbeth and 
colleagues [12] characterized the cellular architecture 
further in their study of 16 resected tophi. Within the 
corona zone, multiple cell types, including macrophages, 
mast cells, and lymphocytes, could be found adjacent to 
osteoclasts. Expression of interleukin-1β was high in this 
region, providing a putative mechanism for osteoclast 
activation and bone resorption, and indeed evidence of 
enhanced osteoclastogenesis has been obtained in vitro 
and in vivo by these authors [13]. MRI has also provided 
information about the morphology of tophi, which can 
vary from ‘discrete nodular masses’ to ill-deﬁ  ned 
amorphous deposits that can spread along anatomical 
planes or in a ‘permeative’ manner without regard to 
compartments, as described by Popp and colleagues [14] 
at the wrist. Clearly, many of these lesions are not 
amenable to resection, leaving only imaging to inform us 
about their position and internal structure.
Figure 1. Plain radiograph of the hands of a Pacifi  c islander man 
with longstanding tophaceous gout. Radiograph shows multiple 
erosions, some of which are extramarginal. Regions of bony lysis 
adjacent to soft tissue densities represent tophi.
Figure 2. Three-dimensional reconstruction of helical 
multidetector computed tomography scan of the foot of 
a patient with tophaceous gout. Tophi at multiple locations, 
including adjacent to the metatarsophalangeal and interphalangeal 
joints of the big toe, are shown. (a) Anteroposterior view and (b) 
lateral view.
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Ultrasound provides a diﬀ  erent ‘sonar’ picture of tophi, 
which may appear as hypoechoic, hyperechoic, or mixed 
echogenicity nodules, as described by Schueller-Weide-
kamm and colleagues [15] (Figure 4). Th   e commonly seen 
surrounding hypoechoic ‘halo’ probably corresponds to 
the outer, loose ﬁ  bro  vascular zone seen on histology [16]. 
Th   ese authors detected ‘dorsal shadowing’ over cartilage 
surfaces causing partial reﬂ  ection of the US wave. Th  is  is 
the same entity as the ‘double contour’ sign (described by 
Th   iele and Schlesinger [17]), whereby an echogenic line 
was detected parallel to the cortex (of, for example, a 
metatarsal head) with an anechoic region between, 
representing hyaline cartilage. MSU crystals have been 
proposed to form in a ﬁ  ne layer like icing sugar over the 
cartilage, but formal conﬁ  rmation of this by comparison 
with histopathology has not been performed, because of 
diﬃ     culty obtaining and analyzing anatomical samples. 
Both ultrasound and MRI scanning can also image the 
inﬂ   ammatory aspect of gouty arthopathy, including 
synovitis, tenosynovitis, and edematous soft tissue 
inﬂ  ammation. Regions of thickened soft tissue that have 
moderate US echogenicity and that might represent 
diﬀ  use  inﬁ   ltration with MSU crystals have been 
described [17]. Evidence of increased vascularization 
within the synovial membrane can be obtained on power 
Doppler images and contrast-enhanced MRI scans [15].
Erosions and bone marrow edema
Bone erosions in gout can be detected by MRI or US and 
may contain enhancing synovium as has been described 
in RA [18]. MRI bone marrow edema also occurs in gout 
and was described by Yu and colleagues [9], in 3 of their 5 
patients, adjacent to intraosseous tophi. Our own recent 
study of the MRI features of gout in 47 patients showed 
bone marrow edema to be present in 36% of those with 
uncomplicated gout (when it was often mild) but to be 
almost universal in those with gout complicated by 
osteomyelitis (when it was usually ﬂ  orid) [19]. In RA, 
MRI bone marrow edema is related to inﬂ  ammatory 
osteitis [5,6]; in osteoarthritis, it is thought to indicate 
ﬁ  brosis and necrosis within subcortical bone [7]. In gout, 
the pathological correlate of MRI bone marrow edema 
remains unknown, and further studies are required to 
elucidate this.
2. Diagnosing gout by using advanced imaging
A diagnosis of gout currently rests on a demonstration of 
MSU crystals in synovial ﬂ  uid or joint tissue or a typical 
clinical picture that might include acute joint swelling of 
abrupt onset and remission within 2 weeks, the occur-
rence of podagra, a raised serum urate, and, in some 
patients, the presence of tophi. According to 2006 Euro-
pean League Against Rheumatism (EULAR) evidence-
based recommendations [20], ‘radiographs have little role 
in diagnosis, though in late or severe gout radiographic 
changes of asymmetrical swelling and subcortical cysts 
without erosion may be useful to diﬀ  erentiate chronic 
gout from other joint conditions’. Th  e contribution of 
advanced imaging would be to assist the diagnosis of 
gout at an earlier phase by revealing acute joint 
inﬂ  ammation, bone erosion, or tophi or a combination of 
these. Ideally, such imaging would identify certain 
speciﬁ  c features that would conﬁ  rm a diagnosis of gout 
without the necessity for joint aspiration. Most of the 
advanced imaging modalities take us some way down this 
path but do not deliver ultimate certainty of diagnosis. 
No study comparing the diagnostic accuracy of any of 
these techniques with the current clinical gold standard 
out  lined above has yet been done.
Magnetic resonance imaging
In clinical practice, MRI scans have been reported as 
useful in diagnosing gout in unusual settings. As reported 
Figure 3. Axial magnetic resonance imaging scans of a large tophus adjacent to the second metatarsal head of a Pacifi  c islander man 
with longstanding tophaceous gout. (a) T1-weighted (T1w) image reveals low-signal intensity tophus. (b) T1w post-contrast image reveals 
rim enhancement and a non-enhancing focus indicating fl  uid within the tophus (arrow). (c) T2-weighted image shows a crescent of fl  uid (white) 
corresponding to the non-enhancing focus on contrast-enhanced images.
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suspected clinically in a patient with fever and low back 
pain, but the MRI revealed a large tophus (conﬁ  rmed on 
aspirate) associated with vertebral destruction. In a similar 
vein, Gardner and McQueen [22] reported tophaceous 
gout of the symphysis pubis (conﬁ  rmed on aspirate), in 
which the presentation had suggested infection or 
malignancy. MRI is an eﬀ  ective tomographic modality to 
image these tophaceous masses, which may not be 
detected clinically if deep below the skin surface. Th  eir 
presence strongly suggests a diagnosis of gout, but 
aspirate conﬁ  rmation is usually required as the diﬀ  eren-
tial diagnosis includes infection or other space-occupying 
lesions.
Ultrasound
Similarly, the US detection of tophi could be helpful in 
diagnosing gout, especially when these lesions are not 
detectable clinically. Perez-Ruiz and colleagues [23], in 
their study of 25 patients with crystal-proven gout, found 
many presumed tophi at ‘hidden’ sites such as under the 
collateral ligaments of the knee. US-guided aspiration of 
12 nodules suspected to be tophi was performed; in 10 of 
these, MSU crystals were obtained, helping to conﬁ  rm 
validity. A larger group of 50 nodules was detected by 
imaging in 22 patients; of these nodules, 37 were detected 
by both MRI and US, 46 were detected by US, and 41 by 
MRI. Th  us, presumably, some false positives and false 
negatives were present for each modality, but deﬁ  ning 
these presents a problem. Benson and colleagues [24] 
have suggested that the sonographic appearances of 
gouty tophi may vary according to developmental state, 
and these features could mimic those of rheumatoid 
nodules, which can also evolve over time. Th  erefore,  the 
ﬁ  nding of a nodule on US, MRI, or CT, while suggestive 
of tophus in the right clinical setting, is not utterly 
diagnostic. Finding bone erosions may also have 
diagnostic relevance, and US has been shown to be more 
sensitive than plain XR for the detection of small 
erosions. In one study of 78 gouty ﬁ   rst  metatarso pha lan-
geal joints, 52 (67%) revealed US erosion compared with 
only 22 (28%) where XR erosions were scored [24]. Th  is 
recalls similar ﬁ   ndings in RA, in which multiplanar 
imaging techniques, including US, MRI, and CT, have all 
been shown to be superior to two-dimensional XR for 
erosion detection [25]. However, the rate of US false 
positives is often diﬃ   cult to determine from the pub-
lished literature; in any case, the imaging appearance of 
erosive, inﬂ  ammatory arthropathy is common to many 
conditions, including RA and PsA as well as gout [15]. 
Th  e prospect that key imaging features such as the 
double-contour sign could conﬁ  rm a diagnosis of gout 
remains tantalizing. Lai and Chiu [26] recently published 
an ultrasound study of large joints (mainly knees and 
ankles) in 34 patients with gout and 46 patients with non-
gouty arthritis and compared sonographic ﬁ  ndings with 
MSU crystal aspiration. Th   e authors reported the double-
contour sign to have a sensitivity of 36.8% and a speci-
ﬁ  city of 97.3% for the diagnosis of gout. However, Carter 
and colleagues [27] were not able to ﬁ  nd US evidence of 
the double-contour sign in any of their ‘index joints’ 
where clinical gout attacks had occurred, and MRI 
erosions were present in more than half.
Computed tomography scanning
Helical multislice CT scanning has a potential role in the 
diagnosis of gout, largely because of the very-high-
resolution 3D images that may be obtained depicting 
Figure 4. Ultrasound image of a subcutaneous tophus of mixed echogenicity with adjacent halo region.
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than MRI images as the slice thickness (which for CT can 
be as low as 0.5 mm) is considerably thinner than that of 
MRI (which is typically 2.5 to 4  mm) and there is no 
interslice gap (in fact, the slices can be reconstructed 
overlapping for 3D reformatting purposes). Th  e density 
of tophi is usually 160 to 170 Hounsﬁ  eld units and this is 
signiﬁ  cantly diﬀ  erent from that of soft tissues and bone 
[29]. Helical CT scanning also has the advantage of allow-
ing imaging of larger regions than most MRI scans, so 
that the pattern of joint involvement can be depicted. In 
gout, this is typically asymmetrical, favoring the meta-
tarso  phalangeal, interphalangeal, and midtarsal joints in 
the feet and the proximal interphalangeal and distal 
inter  phalangeal joints in the hands. Clearly, CT would 
have no role in the diagnosis of acute gout, prior to the 
development of bone erosions or tophi, as it does not 
provide imaging of synovitis, tenosynovitis, or osteitis.
Dual-energy computed tomography
Dual-energy computed tomography (DECT) has estab-
lished roles in cardiology as a means to image calciﬁ    ca tion 
within coronary artery plaques [30] and in renal medicine 
for the identiﬁ  cation of uric acid calculi [31]. However, it 
has also recently been investigated in tophaceous gout 
[32,33]. DECT scanning involves the use of two x-ray tubes 
positioned at 90 degrees to each other (that is, a dual-
source scanner) and two corresponding detectors. Th  is 
allows images to be acquired simul  taneously at two 
diﬀ  erent energy levels, providing two datasets. Th  ese are 
analyzed by using a 3D material decom  position algorithm 
that allows characterization of uric acid (allocated a 
speciﬁ   c color) to be contrasted with calcium and soft 
tissue (allocated other colors) [33] (Figure 5). Th  is  means 
that MSU crystals can be detected with a high degree of 
accuracy, implying that DECT should have very high 
speciﬁ  city for a diagnosis of gout. However, information 
regarding its sensitivity, especially in non-tophaceous 
gout, is prelimi  nary. Choi and colleagues [32] des  cribed 
DECT scanning in 20 tophaceous gout patients who were 
all revealed to have urate deposits in contrast to the control 
group, in whom no deposits were detected. DECT scans 
detected fourfold more deposits than did physical 
examination, indicating the potential of the former for 
imaging subclinical tophi. Nicolaou and colleagues [33] 
described the use of DECT in the successful diagnosis of 
tophaceous gout in ﬁ  ve separate cases in which patients 
presented with soft tissue masses or joint pain. Th  is 
remains an emerging area of great interest.
3. Monitoring disease activity and damage – 
response to therapy
Plain XR provides a very blunt imaging instrument with 
which to try to track the progress of joint damage in gout 
and its response to therapy. McCarthy and colleagues 
[34] studied a group of 39 patients for 10 years and found 
no correlation between XR changes and serum urate 
concentration, and this suggests that XR may not be 
suﬃ   ciently sensitive to monitor change in bony damage 
over this time frame. More recently, a speciﬁ  c  gout 
radiographic scoring method has been developed and 
vali  dated and may improve sensitivity to change in longi-
tudinal studies [2]. With the development of powerful 
and often costly urate-lowering therapies, the focus has 
shifted to the possibility that advanced imaging could be 
useful in this context, providing sensitivity to change over 
a shorter timeframe that would be clinically relevant. Of 
these modalities, MRI and CT have the facility to allow 
storage of standardized digital images and so are 
particularly suitable for use in longitudinal studies.
Perez-Ruiz and colleagues [23] examined the US 
measure  ment of tophi in 25 patients with gout, including 
change in tophus size and its association with serum 
urate concentrations over the course of 12 months. Th  e 
authors reported excellent intraobserver (intraclass 
corre la tion  coeﬃ     cient (ICC) of 0.98 for volume) and 
good interobserver reliability (ICCs of 0.83 for maximal 
diameter and 0.71 for minimal diameter). Th  ey also 
provided data comparing US and MRI diameters of the 
same lesions. Interestingly, these measurements were 
similar but not identical, and the R2 value for the corre-
lation was 0.65. Th   is suggests that deﬁ  nition of the outer 
limit of the tophus may vary according to how it is 
imaged. MRI diameters in this study were generally larger 
than US diameters, and this could be related to better 
imaging (by MRI) of the soft tissue component of the 
Figure 5. Dual-energy computed tomography scan of the foot 
of a Pacifi  c islander man with longstanding gout. Scan reveals 
multiple tophaceous deposits adjacent to interphalangeal and tarsal 
joints as well as the calcaneal bursa, the soft tissues anterior to the 
ankle joint, and the peroneal tendon sheath.
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hypervascularity. In 14 patients, urate-lowering therapy 
(with allopurinol and later benzbromarone in some) was 
commenced, and repeat US examination was performed 
at 12 months. When a reduction greater than the smallest 
detectable diﬀ  erence (SDD) was taken as indicating real 
change, 20 out of 38 tophi were reduced in maximal 
diameter at the endpoint. Th  ese patients had a signiﬁ  -
cantly lower average serum urate than the group in which 
tophus diameter did not change. To look at this another 
way, in patients with an average serum urate of less than 
6  mg/dL, 19 out of 28 tophi (68%) showed reduction 
compared with 1 out of 10 tophi (10%) in patients with 
urate of greater than 6 mg/dL. Th  e authors concluded 
that US fulﬁ  lls the Outcome Measures in Rheumatoid 
Arthritis Clinical Trials (OMERACT) ﬁ  lter [35,36] as a 
feasible, valid, and discriminative measure for evaluating 
changes in tophus size in gout patients on urate-lowering 
therapy.
Schumacher and colleagues [37] performed a multi-
center study assessing the intra- and inter-reader repro-
ducibilities of tophus volume assessment using MRI 
scanning. Volume measurements were made in 17 tophi 
from 14 subjects. Th   ese lesions ranged from very large at 
the elbow (mean volume of 14.1 cm3) to smaller lesions at 
the foot/ankle and hand/wrist (6.9 and 5.3 cm3, respec-
tively). Reproducibility in this study was expressed as the 
absolute percentage diﬀ  erence between volume readings 
taken by one observer twice (intra-reader) or two observers 
(inter-reader). Oddly, intra-reader reproduci  bility in this 
study was slightly worse (17.2% diﬀ  erence  between 
volume readings) than inter-reader reproduci  bility 
(14.2% diﬀ   erence between readers). Th  ese diﬀ  er  ences 
translated into small actual changes in volume (0.07 to 
2.2  cm3). Th  e authors felt that MRI scans without 
gadolinium contrast were optimal for assessing tophus 
volume as post-contrast scans were associated with 
artifact that complicated measurement. It is diﬃ   cult to 
extrapolate from these ﬁ  ndings whether MRI scanning 
would be a suitable tool for assessment of change in 
tophus volume in the therapeutic setting, and further 
studies are required.
CT has been evaluated for assessment of tophus size by 
our own group [28]. Forty-seven hand tophi were analyzed 
from 20 patients with gout, and measurements were 
made with a 16-slice scanner with thin (0.8 mm) slices. 
Two observers separately determined tophus volume 
with the 3D software available. Reliability was very high 
between and within observers (ICCs of 0.989 and 1.0, 
respectively). Physical measurement of subcutaneous 
tophi was also included in this study and, interestingly, 
compared well with CT in terms of reliability. For tophi 
that were identiﬁ  ed by both physical measurement and 
CT (89%), there was good correlation between physical 
measurement of the longest diameter and CT measure-
ment of volume (r = 0.91), providing further validation of 
CT as a measurement instrument. Currently, there are no 
published studies evaluating change in CT tophus 
volume in patients on urate-lowering therapy.
Abufayyah and colleagues [38] recently reported a 
proof-of-concept study investigating the use of DECT in 
monitoring reduction of tophus volume in 12 patients on 
urate-lowering therapy. Scans were performed of four 
peripheral joint areas – elbows, wrists/hands, knees, and 
ankles/feet – at baseline and were repeated 11 to 29 
months later. Ten patients improved on urate-lowering 
therapy, with a reduction in serum urate levels and lower 
frequency of gout attacks. Tophus volume was reduced in 
all of these responders; the median reduction was 64% 
(from 322 to 107 cm3). By contrast, the two non-
responders showed a 36% increase in total tophus 
volume. Th   e authors concluded that DECT scanning had 
potential as a sensitive, quantitative imaging tool for 
assessing tophus (and therefore urate) volume changes in 
patients with tophaceous gout.
Using advanced imaging to monitor responses to 
therapy in arthritic conditions has led to the development 
of measuring instruments by OMERACT-led inter  national 
working parties in RA and PsA [4,39]. Th   e MRI scoring 
systems - Rheumatoid Arthritis MRI Score (RAMRIS) 
and Psoriatic Arthritis MRI Score (PsAMRIS) - are now 
in use in clinical trials and similar systems are being 
evolved for studies in US [40]. Th  e utility of these 
instruments lies in their ability to reproducibly measure 
joint inﬂ   ammation and damage, incorporating charac-
teristic pathological features including bone erosion, 
bone oedema and synovitis for RA, with additions now 
available for scoring tenosynovitis and cartilage [41,42]. 
For PsA, additional features such as bone proliferation 
and peri  articular inﬂ   ammation have been included in 
PsAMRIS to capture relevant pathology [39]. Clearly, 
measuring tophus volume alone in gout is incomplete as 
successful therapy also needs to be associated with a 
reduction in chronic synovitis (or acute ﬂ  ares)  and 
slowing the progression of bone erosion. Th  us, an all-
inclusive measurement tool is needed for compre  hensive 
assessment of gouty arthropathy and perhaps a Gouty 
Arthritis MRI Score or “GAMRIS” is called for. 
Alternatively an US or CT score could be devised for 
gout, keeping in mind that the diﬀ  erent modalities have 
diﬀ  erent strengths and weaknesses. For example, MRI 
has the advantage of revealing all compo  nents 
(inﬂ   ammation, damage, and tophi) but probably has 
lower resolution and reproducibility for tophus measure-
ment than CT scanning, whereas US can reveal all 
components except bone edema (and some deep tissue 
tophi), appears to have fair reproducibility for tophus 
measurement, but tends to be operator-dependent.
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poised to fulﬁ  ll their potential in gout. Th  is review has 
summarized the great advances that have already 
occurred in terms of revealing pathological features in 
this condition. Th  e 3D rendering of tophi is allowing 
computation of volume from CT and MRI, and the 
development of DECT means that tophaceous deposits 
can now be recognized not just by their morphology and 
tissue density characteristics but by their chemical 
compo  sition. US allows a ‘hands on’ approach for the 
practicing clinician to assess tophi, erosions, and syno-
vitis and may be particularly applicable in the longitudinal 
setting. It can also be used to guide aspiration of the joint 
or tophus to obtain material for crystal examination. 
Advances are being made in deﬁ  ning the reproducibility 
of imaging measurements, and ultimately the goal will be 
for the practicing clinician to employ these tools in the 
assessment of the activity and severity of gout and to 
determine clinically meaningful responses to therapy.
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